CytoMed Therapeutics (GDTC)

Executive Summary

CytoMed Therapeutics (SGX: GDTC) is a Singapore-based biopharmaceutical company pioneering novel cell-based immunotherapies for cancer, utilizing gamma-delta (γδ) T cells engineered with chimeric antigen receptor (CAR) technology. The company's lead candidate, CTM-N2D, is an allogeneic CAR-γδ T cell therapy targeting NKG2D ligands expressed on multiple solid tumors. Currently in a Phase 1 clinical trial (NCT05302037) that began enrollment in November 2024, the study is recruiting patients with relapsed/refractory cancers. CytoMed also has an earlier Phase 1 trial (NCT04107142) in colorectal and other solid tumors, though its status is unknown, and a mesenchymal stem cell therapy for aging. As a small-cap public company with a market capitalization of approximately $8.3 million, CytoMed represents an early-stage investment opportunity focused on addressing unmet needs in oncology through its proprietary γδ T cell platform. The company's progress in the clinic, particularly with CTM-N2D, will be critical for near-term value inflection.

Upcoming Catalysts (preview)

• Q3 2026Interim data from Phase 1 CTM-N2D trial40% success
• Q4 2026Potential regulatory filing or IND for CTM-PNK (allogeneic NK cell therapy)25% success
• TBDPartnership or licensing deal for γδ T cell platform20% success